Latest1 information on COVID-19

In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.

Not Recruiting

Trial ID: NCT00788255

Age - 18 Years-40 Years Condition - Obstetrics, Maternal and Fetal Medicine Gender - Female Accepting Healthy Volunteers - No

Purpose

Oxytocin is normally administered following delivery in pregnant patients to reduce postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to assess the coagulation changes of oxytocin in blood samples from pregnant patients using thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic properties of clot formation, and can provide rapid and detailed information about coagulation changes. We aim to collect blood samples from pregnant patients to assess the in-vitro effects of synthetic oxytocin on coagulation using TEG.

Official Title

In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.

Stanford Investigator(s)

Alex Butwick
Alex Butwick

Professor of Anesthesiology, Perioperative and Pain Medicine (OB)

Lindsey Ralls

Clinical Assistant Professor, Anesthesiology, Perioperative and Pain Medicine

Eligibility


Inclusion Criteria:All obstetric patients with singleton pregnancies admitted to the labor
and delivery unit at Lucile Packard Childrens Hospital awaiting elective induction of labor
or elective Cesarean delivery. We will select 25 healthy ASA 1 patients with singleton
pregnancies who are scheduled for uncomplicated elective induction of labor. Gestational
age equal to or greater than 37 weeks.

Exclusion Criteria:Patients with underlying coagulation disorders. Patients with
thrombocytopenia. Patients with pregnancy-induced hypertension, pre-eclampsia. Patients
admitted for non-elective cesarean section. Patients in active labor. Patients requiring
the following medications prior to surgery: NSAIDS, aspirin, anticoagulants.

Patients with significant obstetric or medical disease. No patients <18 years of age will
be recruited.

View More
View Less

Intervention(s):

drug: Final exogenous oxytocin concentration=22.5 μU/mL

drug: Final exogenous oxytocin concentration=30.1μU/mL

drug: Final exogenous oxytocin concentration=32.9μU/mL

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Alexander Butwick

©2022 Stanford Medicine